28-color single tube for flow cytometric assessment of myeloid maturation, myeloid neoplasia, and acute myeloid leukemia minimal/measurable residual disease

被引:0
作者
Gao, Qi [1 ]
Chan, Alexander [1 ]
Zhang, Jingping [1 ]
Sun, Xiaotian [1 ]
Burke, Amanda [1 ]
Miu, Olivia [1 ]
Nguyen, Nghia [1 ]
Zhang, Shu Jie [1 ]
Reminick, Jennifer [1 ]
Wardrope, Jessica [1 ]
Roshal, Mikhail [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, New York, NY USA
关键词
AML; assay validation; LLoD; LLoQ; MPP; MRD; stem cells; IMMUNOPHENOTYPIC ANALYSIS; CELL; AML; EXPRESSION; DIAGNOSIS; FREQUENCY; SUBTYPES; REVEALS; ORIGIN; MARKER;
D O I
10.1002/cyto.b.22233
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Flow cytometry (FC) is an indispensable tool for myeloid neoplasia (MN) diagnosis, and the cell of origin has clinical diagnostic and prognostic significance. However, the complex maturational pathways within the blast compartment complicate the detection of the abnormal population at the minimal/measurable disease (MRD) level using the difference from normal approach. The analysis could be simplified by separating the blast compartment into maturation-defined stages with relatively uniform phenotypes as reference populations. This requires a relatively extensive panel of antibodies to define maturation stages and simultaneously detect the common deviations from the normal pattern. We validated a single tube 28-color clinical assay for MN assessment and acute myeloid leukemia (AML) MRD detection assisted by the precise maturation stage assignment. The new assay uses a previously described 21-antigen backbone, with the additions of CD10, CD36, CD42b, CD45RA, CD90, CD105, and CD371. Validation was performed using 37 normal samples and 151 MN follow-up samples in a split-sample fashion comparing the new assay to the legacy 3-tube, 21-antigen assay. Dilution studies were performed to establish assay sensitivity. A new analysis framework relying on comparison to well-defined maturational stages was established for MRD analysis. The assays showed 100% qualitative concordance with excellent quantitative concordance. Dilution studies yielded a limit of detection of 0.01%. The addition of new antibodies allowed for consistent comparisons of candidate abnormal populations to well-defined normal maturation stages through traditional FC plots and Uniform Matrix Approximation and Projection assessments. This new single-tube, 28-color clinical assay allows for efficient MN assessment in clinical settings. It reliably detects MRD levels of abnormal myeloid cells because the expanded panel allows for precise comparison to defined lineage commitment maturational stages. Lastly, it provides high information density while reducing equipment use, reagent use, and technical labor.
引用
收藏
页数:14
相关论文
共 47 条
  • [1] Advanced Flow Cytometry Analysis Algorithms for Optimizing the Detection of "Different From Normal" Immunophenotypes in Acute Myeloid Blasts
    Aanei, Carmen-Mariana
    Veyrat-Masson, Richard
    Rigollet, Lauren
    Stagnara, Jeremie
    Tardy, Emmanuelle Tavernier
    Daguenet, Elisabeth
    Guyotat, Denis
    Catafal, Lydia Campos
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [2] Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry
    Al-Mawali, Adhra
    Gillis, David
    Hissaria, Pravin
    Lewis, Ian
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (06) : 934 - 945
  • [3] The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
    Alaggio, Rita
    Amador, Catalina
    Anagnostopoulos, Ioannis
    Attygalle, Ayoma D.
    Araujo, Iguaracyra Barreto de Oliveira
    Berti, Emilio
    Bhagat, Govind
    Borges, Anita Maria
    Boyer, Daniel
    Calaminici, Mariarita
    Chadburn, Amy
    Chan, John K. C.
    Cheuk, Wah
    Chng, Wee-Joo
    Choi, John K.
    Chuang, Shih-Sung
    Coupland, Sarah E.
    Czader, Magdalena
    Dave, Sandeep S.
    de Jong, Daphne
    Du, Ming-Qing
    Elenitoba-Johnson, Kojo S.
    Ferry, Judith
    Geyer, Julia
    Gratzinger, Dita
    Guitart, Joan
    Gujral, Sumeet
    Harris, Marian
    Harrison, Christine J.
    Hartmann, Sylvia
    Hochhaus, Andreas
    Jansen, Patty M.
    Karube, Kennosuke
    Kempf, Werner
    Khoury, Joseph
    Kimura, Hiroshi
    Klapper, Wolfram
    Kovach, Alexandra E.
    Kumar, Shaji
    Lazar, Alexander J.
    Lazzi, Stefano
    Leoncini, Lorenzo
    Leung, Nelson
    Leventaki, Vasiliki
    Li, Xiao-Qiu
    Lim, Megan S.
    Liu, Wei-Ping
    Louissaint, Abner, Jr.
    Marcogliese, Andrea
    Medeiros, L. Jeffrey
    [J]. LEUKEMIA, 2022, 36 (07) : 1720 - 1748
  • [4] International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
    Arber, Daniel A.
    Orazi, Attilio
    Hasserjian, Robert P.
    Borowitz, Michael J.
    Calvo, Katherine R.
    Kvasnicka, Hans-Michael
    Wang, Sa A.
    Bagg, Adam
    Barbui, Tiziano
    Branford, Susan
    Bueso-Ramos, Carlos E.
    Cortes, Jorge E.
    Dal Cin, Paola
    DiNardo, Courtney D.
    Dombret, Herve
    Duncavage, Eric J.
    Ebert, Benjamin L.
    Estey, Elihu H.
    Facchetti, Fabio
    Foucar, Kathryn
    Gangat, Naseema
    Gianelli, Umberto
    Godley, Lucy A.
    Gokbuget, Nicola
    Gotlib, Jason
    Hellstrom-Lindberg, Eva
    Hobbs, Gabriela S.
    Hoffman, Ronald
    Jabbour, Elias J.
    Kiladjian, Jean-Jacques
    Larson, Richard A.
    Le Beau, Michelle M.
    Loh, Mignon L. -C.
    Lowenberg, Bob
    Macintyre, Elizabeth
    Malcovati, Luca
    Mullighan, Charles G.
    Niemeyer, Charlotte
    Odenike, Olatoyosi M.
    Ogawa, Seishi
    Orfao, Alberto
    Papaemmanuil, Elli
    Passamonti, Francesco
    Porkka, Kimmo
    Pui, Ching-Hon
    Radich, Jerald P.
    Reiter, Andreas
    Rozman, Maria
    Rudelius, Martina
    Savona, Michael R.
    [J]. BLOOD, 2022, 140 (11) : 1200 - 1228
  • [5] High frequency of immunophenotype changes in acute myeloid leukemia at relapse:: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)
    Baer, MR
    Stewart, GC
    Dodge, RK
    Leget, G
    Sulé, N
    Mrózek, K
    Schiffer, CA
    Powel, BL
    Kolitz, JE
    Moore, JO
    Stone, RM
    Davey, FR
    Carrol, AJ
    Larson, RA
    Bloomfield, CD
    [J]. BLOOD, 2001, 97 (11) : 3574 - 3580
  • [6] Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis
    Chen, Xueyan
    Cherian, Sindhu
    [J]. CLINICS IN LABORATORY MEDICINE, 2017, 37 (04) : 753 - +
  • [7] Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities
    Chen, Xueyan
    Wood, Brent L.
    [J]. BLOOD REVIEWS, 2017, 31 (02) : 63 - 75
  • [8] CLSI, 2021, CLSI guideline H62, V1st ed.
  • [9] Immunophenotyping for diagnosis and prognosis in MDS: Ready for general application?
    Cremers, Eline M. P.
    Westers, Theresia M.
    Ossenkoppele, Gert J.
    van de Loosdrecht, Arjan A.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2015, 28 (01) : 14 - 21
  • [10] Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
    Doehner, Hartmut
    Wei, Andrew H.
    Appelbaum, Frederick R.
    Craddock, Charles
    DiNardo, Courtney D.
    Dombret, Herve
    Ebert, Benjamin L.
    Fenaux, Pierre
    Godley, Lucy A.
    Hasserjian, Robert P.
    Larson, Richard A.
    Levine, Ross L.
    Miyazaki, Yasushi
    Niederwieser, Dietger
    Ossenkoppele, Gert
    Roellig, Christoph
    Sierra, Jorge
    Stein, Eytan M.
    Tallman, Martin S.
    Tien, Hwei-Fang
    Wang, Jianxiang
    Wierzbowska, Agnieszka
    Lowenberg, Bob
    [J]. BLOOD, 2022, 140 (12) : 1345 - 1377